SLL

14 registered clinical trials studyying SLL — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL NCT07342478	Newave Pharmaceutical Inc	Phase 3
Recruiting	Anti CD19 CAR-T Combined With BTKi to Treat Newly Diagnosed High-risk CLL/SLL NCT07120633	The Affiliated Hospital of Xuzhou Medical University	N/A
Recruiting	Study of Epcoritamab as a Consolidation Therapy in CLL/SLL NCT07108998	Zulfa Omer	Phase 2
Recruiting	A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refract NCT05947851	Merck Sharp & Dohme LLC	Phase 3
Recruiting	CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia NCT04704323	Catapult Therapeutics	Phase 1
Terminated	Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocy NCT04806035	TG Therapeutics, Inc.	Phase 1
Withdrawn	A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lym NCT04694560	Memorial Sloan Kettering Cancer Center	—
Withdrawn	Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL NCT03639324	Virginia Commonwealth University	Phase 1
Terminated	Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL NCT03572634	Sumitomo Pharma America, Inc.	Phase 1 / Phase 2
Terminated	Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL) NCT02046928	Ångstrom Pharmaceuticals	Phase 2
Recruiting	Registry of the German CLL Study Group NCT02863692	German CLL Study Group	—
Terminated	Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL NCT01465334	Dana-Farber Cancer Institute	Phase 2
Completed	Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymp NCT00980395	University of Arizona	Phase 2
Completed	Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL NCT00546793	Gilead Sciences	Phase 1 / Phase 2